DOI: http://dx.doi.org/10.18203/2349-2902.isj20195958

Male breast cancer a rare entity: the experience from North-East India

Gaurav Das, Jitin Yadav, Joydeep Purkayastha, Abhijit Talukdar, Sachin Khanna

Abstract


Background: Breast cancer is one of the most common malignancy among women but it is not common in men. Male breast cancer (MBC) is a rare disease and accounts for ∼1% of all cancers in men. There is lack of data related to MBC. The objective was to study the clinic-pathological characteristics and outcome of MBC patients at this institute.

Methods: It is a retrospective study. Author analyzed clinico-pathological factors, management and follow up details of all patients with MBC from 2012 to 2018 at the cancer centre.

Results: Total 20 patients were included in the study. No risk factor identified in any patient. The median age at diagnosis was 57.5 years. Most common location was central quadrant. Most common stage at presentation was stage 3. Fifteen patients underwent upfront surgery while neoadjuvant chemotherapy was given to two patients. One patient had complete pathological response (cPR). The median follow up was 24 months (4-60 months). Three patients developed local recurrence (3 chest wall and 1 axilla). Two patients developed distant metastasis (lung, liver and bone). Actual overall survival rate at 5 years was 67.5% with median disease-free survival was 55%.

Conclusions: Multicentric trials are necessary to understand the predictive and prognostic markers and to improve the outcome in male breast cancer.


Keywords


Breast cancer, Breast conservation surgery, Male breast cancer

Full Text:

PDF

References


Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006;367(9510):595-604.

Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M, López Gómez M, Casado E. Male breast cancer. Cancer Treat Rev. 2010;36(6):451-7.

Tajima N, Tsukuma H, Oshima A. Descriptive epidemiology of male breast cancer in Osaka, Japan. J Epidemiol. 2001;11(1):1-7.

Fiala L, Coufal O, Fait V, Foretova L. Male breast cancer--our experience. Rozhledy v chirurgii: mesicnik Ceskoslovenske chirurgicke spolecnosti. 2010;89(10):612-8.

Sasco AJ, Lowenfels AB, Jong PP. Epidemiology of male breast cancer. A meta‐analysis of published case‐control studies and discussion of selected aetiological factors. Intern J Cancer. 1993;53(4):538-49.

Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Gene. 1996;13(1):123.

Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg Å. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res. 1998;58(7):1367-71.

Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H, Stemhagen A, et al. Breast cancer in men: aspects of familial aggregation. JNCI: J Nat Cancer Institute. 1991;83(12):849-54.

Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H, Stemhagen A, et al. Breast cancer in men: Aspects of familial aggregation. J Natl Cancer Inst. 1991;83:849-54.

Sørensen HT, Friis S, Olsen JH, Thulstrup AM, Mellemkjaer L, Linet M, et al. Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol. 1998;93(2):231-3.

Rosenblatt KA, Thomas DB, Jimenez LM, Fish B, McTiernan A, Stalsberg H, et al. The relationship between diet and breast cancer in men (United States). Cancer Causes Control. 1999;10:107-13.

Erren TC. A meta-analysis of epidemiologic studies of electric and magnetic fields and breast cancer in women and men. Bioelectromagnetics. 2001;22 Suppl 5:105-19.

Hsing AW, McLaughlin JK, Cocco P, Chien HT, Fraumeni JF. Risk factors for male breast cancer (United States). Cancer Causes Control. 1998;9(3):269-75.

Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treatment. 2009;115(2):429-30.

Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol/Hematol. 2010;73(3):246-54.

Hill TD, Khamis HJ, Tyczynski JE. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Annals Epidemiol. 2005;15(10):773-80.

Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Annals Int Med. 2002;137(8):678-87.

Wick MR, Sayadi H, Ritter JH, Hill DA, Reddy VB, Gattuso P. Low-stage carcinoma of the male breast: a histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol. 1999;111(1):59-69.

Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001;182:389-92.

Rudlowski C, Friedrichs N, Faridi A, Füzesi L, Moll R, Bastert G, et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat. 2004;84(3):215-23.

Hecht JR, Winchester DJ. Male breast cancer. Am J Clin Pathol. 1994;102:S25-S30.

Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Nat Cancer Institute. 2000;92(14):1126-35.

Ouriel K, Lotze MT, Hinshaw JR. Prognostic factors of carcinoma of the male breast. Surg Gynecol Obstet. 1984;159:373-6.

Gough DB, Donohue JH, Evans MM, Pernicone PJ, Wold LE, Naessens JM, et al. A 50-year experience of male breast cancer: is outcome changing?. Surgical Oncol. 1993;2(6):325-33.

Cutuli B, Lacroze M, Dilhuydy JM, Veiten M, De Lafontan B, Marchal C, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Euro J Cancer. 1995;31(12):1960-4.